These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2573101)

  • 21. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine.
    Sprah L; Zivin M; Sket D
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1093-100. PubMed ID: 10027846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys.
    Doan VD; Grondin R; Hadj Tahar A; Grégoire L; Bédard PJ
    Clin Neuropharmacol; 1999; 22(5):281-7. PubMed ID: 10516879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
    Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
    J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors.
    Takashima H; Tsujihata M; Kishikawa M; Freed WJ
    Exp Neurol; 1999 Sep; 159(1):98-104. PubMed ID: 10486178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Psychotropic drugs as tools for clinical research into schizophrenia (author's transl)].
    Beckmann H
    Fortschr Neurol Psychiatr Grenzgeb; 1978 Oct; 46(10):564-77. PubMed ID: 29831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine involvement in the migraine attack.
    Fanciullacci M; Alessandri M; Del Rosso A
    Funct Neurol; 2000; 15 Suppl 3():171-81. PubMed ID: 11200788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.
    Wetzel H; Hillert A; Gründer G; Benkert O
    Am J Psychiatry; 1994 Oct; 151(10):1499-502. PubMed ID: 7916543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paradoxical reaction to L-dopa in schizophrenic patients.
    Alpert M; Friedhoff AJ; Marcos LR; Diamond F
    Am J Psychiatry; 1978 Nov; 135(11):1329-32. PubMed ID: 707630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disruption of spine homeostasis causes dopaminergic compensatory up-regulation, resulting in schizophrenia.
    Sato K
    Med Hypotheses; 2012 Sep; 79(3):304-7. PubMed ID: 22683237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An un-dopamine hypothesis of schizophrenia.
    Alpert M; Friedhoff AJ
    Schizophr Bull; 1980; 6(3):387-9. PubMed ID: 6105705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine agonists in schizophrenia: a review.
    Benkert O; Müller-Siecheneder F; Wetzel H
    Eur Neuropsychopharmacol; 1995; 5 Suppl():43-53. PubMed ID: 8775758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia.
    Pickar D; Litman RE; Konicki PE; Wolkowitz OM; Breier A
    Mod Probl Pharmacopsychiatry; 1990; 24():124-51. PubMed ID: 1970851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine autoreceptor stimulation: clinical significance.
    Meltzer HY
    Pharmacol Biochem Behav; 1982; 17 Suppl 1():1-10. PubMed ID: 6223322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.